MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4
Clinical safety rating
cautionComprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4).
Provides essential electrolytes (calcium, magnesium, potassium, sodium, acetate, chloride) to maintain or restore electrolyte balance, acid-base equilibrium, and osmotic pressure in extracellular fluid. Calcium and magnesium are critical for neuromuscular function and enzymatic reactions. Acetate is metabolized to bicarbonate in the liver and peripheral tissues, serving as an alkalinizing agent to correct acidosis.
| Metabolism | Acetate is metabolized to bicarbonate in the liver and peripheral tissues via acetyl-CoA and the Krebs cycle. Electrolytes (calcium, magnesium, potassium, sodium, chloride) are not metabolized and are excreted primarily renally, with minor losses via feces and sweat. |
| Excretion | Renal: >95% as infused electrolytes via glomerular filtration and tubular handling. Biliary/fecal: <5% in normal renal function. |
| Half-life | Not applicable as components are endogenous; exogenous electrolytes have functional half-lives of minutes to hours depending on compartment equilibration. |
| Protein binding | Negligible (<5%); electrolytes are free ions in plasma. |
| Volume of Distribution | Varies by ion: Na+ ~0.5 L/kg (extracellular), K+ ~4 L/kg (intracellular), Cl- ~0.3 L/kg. Overall composite Vd ~0.2-0.5 L/kg. |
| Bioavailability | Intravenous: 100% (complete). |
| Onset of Action | Intravenous: Immediate (within seconds) as electrolytes distribute directly into vascular compartment. |
| Duration of Action | Intravenous: 1-4 hours for acute correction of deficits; sustained effect requires continuous infusion or repeated doses. |
| Molecular Weight | Not applicable as this is a mixture of electrolytes; individual ions have molecular weights: Na+ 22.99 Da, K+ 39.10 Da, Ca2+ 40.08 Da, Mg2+ 24.31 Da, Cl- 35.45 Da. The combined formulation does not have a single molecular weight. |
Intravenous infusion; dose determined by individual electrolyte requirements and fluid status. Typical adult dose: 500-1000 mL as a continuous infusion at a rate of 100-200 mL/hour, not to exceed 3 L/day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: Reduce infusion rate by 50%; monitor serum electrolytes closely. GFR <30 mL/min: Avoid use due to risk of hyperkalemia and hyperphosphatemia; use alternative electrolyte preparation. |
| Liver impairment | Child-Pugh Class C: Avoid use due to risk of fluid overload and electrolyte imbalances; consider alternative with lower volume and adjusted electrolyte content. |
| Pediatric use | Weight-based: 20-40 mL/kg/day as continuous infusion; adjust rate based on serum electrolytes and fluid balance. Maximum infusion rate: 100 mL/hour. |
| Geriatric use | Use with caution due to age-related decline in renal function. Start at lower infusion rate (50-100 mL/hour) and monitor electrolytes, fluid balance, and cardiac function closely. |
| 1st trimester | Multiple Electrolytes Injection Type 1 USP pH 7.4 is generally considered safe during the first trimester when used for appropriate clinical indications. However, as with all intravenous fluids, use only if clearly needed, as electrolyte imbalances can affect maternal and fetal homeostasis. No teratogenic effects have been reported with standard electrolyte compositions. |
| 2nd trimester | Safe for use during the second trimester when clinically indicated. Monitor electrolyte levels closely to avoid imbalances that could affect pregnancy outcomes. |
| 3rd trimester | Safe for use during the third trimester, but careful monitoring of fluid and electrolyte status is recommended, especially in conditions like preeclampsia or gestational hypertension, where volume status must be managed cautiously. |
Clinical note
Comprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4).
| Placental transfer | Electrolytes (sodium, potassium, chloride, calcium, magnesium, etc.) are known to cross the placenta readily by active transport and diffusion to maintain fetal homeostasis. The degree of transfer is physiologic and balanced by maternal-fetal exchange mechanisms. Administration of this solution is unlikely to cause adverse fetal effects when given at appropriate rates and volumes. |
| Breastfeeding | Multiple Electrolytes Injection Type 1 USP pH 7.4 is compatible with breastfeeding. Electrolytes are normal constituents of breast milk and maternal administration does not pose a risk to the infant. However, consider the underlying condition requiring the infusion and potential effects on lactation (e.g., dehydration or electrolyte disturbances). |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No studies in pregnant women; animal reproduction studies not conducted. Contains electrolytes at physiologic concentrations: sodium 140 mEq/L, potassium 5 mEq/L, calcium 2.5 mEq/L, magnesium 1.5 mEq/L, chloride 98 mEq/L, acetate 27 mEq/L, gluconate 23 mEq/L. No known teratogenic effects at therapeutic doses. Risk of electrolyte imbalance if administered inappropriately. |
| Fetal Monitoring | Monitor maternal serum electrolytes (Na, K, Ca, Mg, Cl, bicarbonate), renal function, fluid balance, and ECG during prolonged therapy. Fetal monitoring via ultrasound for signs of hydrops or arrhythmias if maternal electrolyte disturbances occur. |
| Fertility Effects | No known adverse effects on fertility at recommended doses. Severe electrolyte disturbances may impair reproductive function. |
■ FDA Black Box Warning
None
| Serious Effects |
Severe hypernatremia or hyponatremia unless specifically indicated for correctionSevere hyperkalemia or hypokalemia unless specifically indicatedSevere hypercalcemia or hypocalcemia unless specifically indicatedSevere hypermagnesemia or hypomagnesemia unless specifically indicatedSevere fluid overload (e.g., congestive heart failure, pulmonary edema)Anuria or severe renal impairment without appropriate dose adjustment
| Precautions | Risk of fluid and/or solute overload leading to dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema, Risk of aluminum toxicity in patients with impaired renal function due to aluminum content of the injection, Avoid rapid administration of calcium-containing solutions to prevent hypercalcemia and cardiac arrhythmias, Monitor serum electrolytes, renal function, and acid-base balance during therapy, Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia (e.g., burns, severe trauma) due to potassium content, Do not use if solution is discolored or contains precipitate; use administration set with filter |
| Food/Dietary | No specific food interactions. However, electrolyte balance may be affected by dietary intake; patients should maintain a balanced diet as advised by their clinician. |
| Clinical Pearls | Contains sodium chloride, potassium chloride, magnesium chloride, and sodium acetate in a pH 7.4 buffer. Used as a source of water and electrolytes for maintenance or replacement therapy. Monitor serum electrolytes, particularly potassium and magnesium, in renal impairment. Do not administer unless solution is clear and container undamaged. Use with caution in patients with heart failure, renal failure, or hyperkalemia. |
| Patient Advice | This solution is given intravenously to replace fluids and electrolytes. · Inform your healthcare provider if you have kidney disease, heart disease, or high potassium levels. · Report any signs of fluid overload such as shortness of breath, swelling in the ankles or feet. · Do not suddenly stop or change the infusion rate without consulting your doctor. · Seek immediate medical attention if you experience chest pain, irregular heartbeat, or muscle weakness. |
Loading safety data…